ZAP70 in B-CLL cells related to the expression in NK cells is a surrogate marker for mutational status
© 2013 Clinical Cytometry Society..
The strongest prognostic factor in chronic B-cell lymphocytic leukemia (CLL) is the mutational status of the immunoglobulin heavy chain variable region (IGHV) genes. Determination of this mutational status is laborious and therefore not applied in routine diagnostics. A search for "surrogate markers" has been conducted over the past few years. One of the most promising surrogate markers is ZAP70, but standardization of the measurement of ZAP70 has proven to be difficult. Conventionally, ZAP70 expression in CLL cells is related to ZAP70 expression in T cells. We propose a new method in which ZAP70 expression in NK cells is used as reference (new NK-MFI method). We have measured ZAP70 expression in samples of 45 previously untreated CLL patients. ZAP70 in CLL cells related to ZAP70 in NK cells correlated better to cytogenetic risk profile and mutational status than the conventional methods. Negativity of both ZAP70 (new NK-MFI method) and CD38 resulted in a probability of 90% for mutated IGHV genes. In conclusion, ZAP70 expression in CLL cells related to ZAP70 expression in NK cells is a better surrogate marker for mutational status than the conventional T cell related methods.
Medienart: |
E-Artikel |
---|
Erscheinungsjahr: |
2014 |
---|---|
Erschienen: |
2014 |
Enthalten in: |
Zur Gesamtaufnahme - volume:86 |
---|---|
Enthalten in: |
Cytometry. Part B, Clinical cytometry - 86(2014), 4 vom: 28. Juli, Seite 280-7 |
Sprache: |
Englisch |
---|
Beteiligte Personen: |
Wiggers, Tom G H [VerfasserIn] |
---|
Links: |
---|
Themen: |
Biomarkers, Tumor |
---|
Anmerkungen: |
Date Completed 07.04.2015 Date Revised 19.11.2015 published: Print-Electronic Citation Status MEDLINE |
---|
doi: |
10.1002/cyto.b.21132 |
---|
funding: |
|
---|---|
Förderinstitution / Projekttitel: |
|
PPN (Katalog-ID): |
NLM239140613 |
---|
LEADER | 01000naa a22002652 4500 | ||
---|---|---|---|
001 | NLM239140613 | ||
003 | DE-627 | ||
005 | 20231224115312.0 | ||
007 | cr uuu---uuuuu | ||
008 | 231224s2014 xx |||||o 00| ||eng c | ||
024 | 7 | |a 10.1002/cyto.b.21132 |2 doi | |
028 | 5 | 2 | |a pubmed24n0797.xml |
035 | |a (DE-627)NLM239140613 | ||
035 | |a (NLM)24924909 | ||
040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
041 | |a eng | ||
100 | 1 | |a Wiggers, Tom G H |e verfasserin |4 aut | |
245 | 1 | 0 | |a ZAP70 in B-CLL cells related to the expression in NK cells is a surrogate marker for mutational status |
264 | 1 | |c 2014 | |
336 | |a Text |b txt |2 rdacontent | ||
337 | |a ƒaComputermedien |b c |2 rdamedia | ||
338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
500 | |a Date Completed 07.04.2015 | ||
500 | |a Date Revised 19.11.2015 | ||
500 | |a published: Print-Electronic | ||
500 | |a Citation Status MEDLINE | ||
520 | |a © 2013 Clinical Cytometry Society. | ||
520 | |a The strongest prognostic factor in chronic B-cell lymphocytic leukemia (CLL) is the mutational status of the immunoglobulin heavy chain variable region (IGHV) genes. Determination of this mutational status is laborious and therefore not applied in routine diagnostics. A search for "surrogate markers" has been conducted over the past few years. One of the most promising surrogate markers is ZAP70, but standardization of the measurement of ZAP70 has proven to be difficult. Conventionally, ZAP70 expression in CLL cells is related to ZAP70 expression in T cells. We propose a new method in which ZAP70 expression in NK cells is used as reference (new NK-MFI method). We have measured ZAP70 expression in samples of 45 previously untreated CLL patients. ZAP70 in CLL cells related to ZAP70 in NK cells correlated better to cytogenetic risk profile and mutational status than the conventional methods. Negativity of both ZAP70 (new NK-MFI method) and CD38 resulted in a probability of 90% for mutated IGHV genes. In conclusion, ZAP70 expression in CLL cells related to ZAP70 expression in NK cells is a better surrogate marker for mutational status than the conventional T cell related methods | ||
650 | 4 | |a Journal Article | |
650 | 4 | |a CD38 | |
650 | 4 | |a NK cells | |
650 | 4 | |a ZAP70 | |
650 | 4 | |a chronic lymphocytic leukemia | |
650 | 4 | |a mutational status | |
650 | 4 | |a prognosis | |
650 | 7 | |a Biomarkers, Tumor |2 NLM | |
650 | 7 | |a ZAP-70 Protein-Tyrosine Kinase |2 NLM | |
650 | 7 | |a EC 2.7.10.2 |2 NLM | |
650 | 7 | |a ZAP70 protein, human |2 NLM | |
650 | 7 | |a EC 2.7.10.2 |2 NLM | |
700 | 1 | |a Westra, Guus |e verfasserin |4 aut | |
700 | 1 | |a Westers, Theresia M |e verfasserin |4 aut | |
700 | 1 | |a Abbes, Andre P |e verfasserin |4 aut | |
700 | 1 | |a Strunk, Annuska |e verfasserin |4 aut | |
700 | 1 | |a Kuiper-Kramer, Ellen |e verfasserin |4 aut | |
700 | 1 | |a Poddighe, Pino |e verfasserin |4 aut | |
700 | 1 | |a van de Loosdrecht, Arjan A |e verfasserin |4 aut | |
700 | 1 | |a Chamuleau, Martine E D |e verfasserin |4 aut | |
773 | 0 | 8 | |i Enthalten in |t Cytometry. Part B, Clinical cytometry |d 2003 |g 86(2014), 4 vom: 28. Juli, Seite 280-7 |w (DE-627)NLM122834577 |x 1552-4957 |7 nnns |
773 | 1 | 8 | |g volume:86 |g year:2014 |g number:4 |g day:28 |g month:07 |g pages:280-7 |
856 | 4 | 0 | |u http://dx.doi.org/10.1002/cyto.b.21132 |3 Volltext |
912 | |a GBV_USEFLAG_A | ||
912 | |a GBV_NLM | ||
951 | |a AR | ||
952 | |d 86 |j 2014 |e 4 |b 28 |c 07 |h 280-7 |